Nothing said here yet.
to join the conversation.
| Kohlberg Isaac T.Director | Sell | 24,000 | $109.2K | Tue, Sep 15 |
| OCONNELL MAUREENDirector | Sell | 12,466 | $57.0K | Thu, Sep 3 |
| OCONNELL MAUREENDirector | Sell | 20,534 | $95.1K | Wed, Sep 2 |
| OCONNELL MAUREENDirector | Sell | 10,000 | $46.0K | Wed, Aug 19 |
Led by CEO Cagen Williams, the group brings together NECC and the combined Bel-Mac, connecting established regional businesses across the Mid-Atlantic and Gulf Coast. ALEXANDRIA, Va., Oct.
Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM
ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM
IP licensing settlement drives record $114.6M revenue amid Life Sciences write-down.
Acacia Research Corp (ACTG) reports a 124% revenue surge to $114.6 million, driven by a major IP settlement and record energy performance, while navigating a life sciences writedown.
Before MJ and Mike begin their prepared remarks, please be reminded that certain information provided during this call may contain forward-looking statements relating to current expectations, estimates, forecasts and projections about future events that are…
Moby summary of Acacia Research Corporation's Q1 2026 earnings call
Acacia Research (NASDAQ:ACTG) executives highlighted improving operating performance at the company’s energy and industrial businesses and continued cost actions at its manufacturing unit, while also acknowledging the inherently “episodic” nature of…
Acacia Research Corporation (NASDAQ:ACTG) is one of the High-Flying Penny Stocks to Buy.
Acacia Research Corp (ACTG) reports a record full-year revenue of $285.2 million, showcasing strong operational performance despite macroeconomic headwinds.